Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma

Southern Medical Journal

Volumn 100, Issue 3, 2007, Pages 328-330

  Dasanu, Constantin A ^a,b   Dutcher, Janice ^a   Alexandrescu, Doru T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Hand foot syndrome; Multitargeted tyrosine kinase inhibitors (TKIs); Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RAF PROTEIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DESQUAMATION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LABORATORY TEST; MALE; MEDICAL EXAMINATION; SKIN DISCOLORATION; ACRODERMATITIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ERYTHEMA; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PIGMENT DISORDER; SPINAL CORD TUMOR;

ACRODERMATITIS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; ERYTHEMA; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIGMENTATION DISORDERS; PROTEIN KINASE INHIBITORS; PYRIDINES; RAF KINASES; SPINAL NEOPLASMS;

EID: 34247589719     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31802f01a9     Document Type: Article

References (12)

1. Robert C, Soria JC, Spats A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
2. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
3. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
4. Sorafenib Monograph. DrugDex in Micromedex Healthcare Series. Accessed July 2, 2006.
5. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-6392S.
6. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
7. Arya V, Grzybowski J, Schwartz RA. Carotenemia. Cutis 2003;71:441-442.
8. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician 2004;69:299-304.
9. Aktuna D, Buchinger W, Lansteger W, et al. Beta-carotene, vitamin A and carrier proteins in thyroid diseases. Acta Med Austriaca 1993;20:17-20.
10. Chitturi S, Dakkak M, Campbell AP. Skin fragility and abnormal liver function tests. Postgrad Med J 1999;75:435-437.
11. Kong MF, Jeffcoate W. Eighty-six cases of Addison's disease. Clin Endocrinol (Oxf) 1994;41:757-761.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-245.